E

Exact Sciences Corporation (EXAS)

NCM – Real vaqt narxi. Valyuta: USD

104.91

0.00 (0.00%)

Yopilishda: Mar 20, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

E

Exact Sciences Corporation (EXAS)

NCM – Real vaqt narxi. Valyuta: USD

104.91

0.00 (0.00%)

Yopilishda: Mar 20, 2026, 4:00 PM EDT

16.04.2026

Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag

Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly profit and revenue, but flagged a hit to its 2026 earnings outlook from its recently completed cancer diagnostics acquisition. Investors weighed near-term earnings strength against dilution from the company's roughly $23 billion acquisition of Exact Sciences.

17.03.2026

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri.

11.03.2026

Exact Sciences (EXAS) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

04.03.2026

CSLLY or EXAS: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?

04.03.2026

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world. Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to t.

03.03.2026

Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rat.

20.02.2026

Exact Sciences Stockholders Approve Acquisition by Abbott

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.

Videolar

No Data

There is no data to display

Press-relizlar

04.03.2026

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world. Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to t.

03.03.2026

Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rat.

20.02.2026

Exact Sciences Stockholders Approve Acquisition by Abbott

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.

13.02.2026

Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for the fourth quarter of 2025 and $3.25 billion for the full year of 2025, both ended December 31, 2025. “In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests.

Search stocks

Exact Sciences Corporation (EXAS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Exact Sciences Corporation (EXAS)

Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

Exact Sciences (EXAS) is a Top-Ranked Momentum Stock: Should You Buy?

CSLLY or EXAS: Which Is the Better Value Stock Right Now?

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

Exact Sciences Stockholders Approve Acquisition by Abbott

Videolar

No Data

Press-relizlar

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

Exact Sciences Stockholders Approve Acquisition by Abbott

Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results